Meropenem Ranbaxy (Uk)

Meropenem, the active ingredient in Meropenem Ranbaxy (Uk), is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats serious bacterial infections such as intra‑abdominal sepsis, hospital‑acquired pneumonia and meningitis in hospitalized patients.

GNH USA supplies Meropenem Ranbaxy (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides bacterial clearance in severe abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens in hospital‑acquired UTIs. - Nosocomial pneumonia: effective against ventilator‑associated and ICU‑acquired pneumonia. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. - Septicemia: rapidly reduces bacterial load in bloodstream infections.

Adverse reactions may occur with any intravenous antibiotic. Monitoring for side effects is recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Infusion site reactions: erythema or phlebitis at the injection site. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated colitis: severe diarrhea with pseudomembranous colitis. - Anaphylaxis: acute hypersensitivity reaction requiring emergency care. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Renal toxicity: acute kidney injury in susceptible individuals. - Hepatic failure: rare but possible severe liver injury.

Use meropenem with caution in specific clinical situations and follow handling guidelines. - Renal function: adjust dose in patients with impaired clearance. - Allergy: avoid in individuals with known carbapenem or beta‑lactam hypersensitivity. - Seizure risk: monitor closely in patients with a history of epilepsy or CNS disorders. - Pregnancy: prescribe only when benefits outweigh potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other agents, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Aminoglycosides (e.g., gentamicin): additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance renal clearance of meropenem; adjust dose if needed. - Anticoagulants (e.g., warfarin): occasional alteration of INR; check coagulation parameters.